UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 116

Sortiert nach

Checkpoint blockade in the treatment of breast cancer: current status and future directions

British journal of cancer, 2018-07, Vol.119 (1), p.4-11

2018

Volltextzugriff (PDF)

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

The lancet oncology, 2017-01, Vol.18 (1), p.52-62

2017

Volltextzugriff (PDF)

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

Nature medicine, 2018-07, Vol.24 (7), p.986-993

2018

Volltextzugriff (PDF)

Tissue-resident memory T cells in breast cancer control and immunotherapy responses

Nature reviews. Clinical oncology, 2020-06, Vol.17 (6), p.341-348

2020

Volltextzugriff (PDF)

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer

Pathology, 2017-02, Vol.49 (2), p.141-155

2017

Volltextzugriff (PDF)

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy

Oncotarget, 2019-07, Vol.10 (45), p.4612-4614

2019

Volltextzugriff (PDF)

Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2017-11, Vol.77 (22), p.6340-6352

2017

Volltextzugriff (PDF)

Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions

Frontiers in oncology, 2017-08, Vol.7, p.156-156

2017

Volltextzugriff (PDF)

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

Nature communications, 2017-09, Vol.8 (1), p.606-18, Article 606

2017

Volltextzugriff (PDF)

Clinical implications of prospective genomic profiling of metastatic breast cancer patients

Breast cancer research : BCR, 2020-08, Vol.22 (1), p.91-91, Article 91

2020

Volltextzugriff (PDF)

Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer

JNCI : Journal of the National Cancer Institute, 2022-03, Vol.114 (3), p.467-470

2022

Volltextzugriff (PDF)

Equitable Access to Genomic Molecular Testing for Australian Cancer Patients: Insights from the Victorian Precision Oncology Summit

Current oncology (Toronto), 2024-08, Vol.31 (8), p.4519-4530

2024

Volltextzugriff (PDF)

Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies

European journal of cancer (1990), 2024-02, Vol.198, p.113503-113503, Article 113503

2024

Volltextzugriff (PDF)

Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer

JNCI : Journal of the National Cancer Institute, 2023-07, Vol.115 (7), p.805-814

2023

Volltextzugriff (PDF)

Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients

Breast cancer research : BCR, 2022-07, Vol.24 (1), p.1-50, Article 50

2022

Volltextzugriff (PDF)

Extended adjuvant aromatase inhibitor therapy: less is more

Med (New York, N.Y. : Online), 2021-09, Vol.2 (9), p.996-998

2021

Volltextzugriff (PDF)

A pituitary metastasis, an adenoma and potential hypophysitis: A case report of tumour to tumour metastasis in the pituitary

Journal of clinical neuroscience, 2020-11, Vol.81, p.161-166

2020

Volltextzugriff (PDF)

Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm

Targeted oncology, 2022-09, Vol.17 (5), p.539-548

2022

Volltextzugriff (PDF)

Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study

Cancer discovery, 2022-09, Vol.12 (9), p.2058-2073

2022

Volltextzugriff (PDF)

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

Cancer medicine (Malden, MA), 2024-07, Vol.13 (13), p.e7385-n/a

2024

Volltextzugriff (PDF)

Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012–2022

Asia-Pacific journal of clinical oncology, 2024-06

2024

Volltextzugriff (PDF)

Advancing Immunotherapy in Metastatic Breast Cancer

Current treatment options in oncology, 2017-06, Vol.18 (6), p.35-35, Article 35

2017

Volltextzugriff (PDF)

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer

NPJ breast cancer, 2023-08, Vol.9 (1), p.68-68, Article 68

2023

Volltextzugriff (PDF)

Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma

Journal of personalized medicine, 2024-01, Vol.14 (2), p.128

2024

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Englisch
(116)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(9)
Resuscitation
(7)
Journal Of Clinical Oncology
(6)
Clinical Cardiology
(5)
Journal Of The American College Of Cardiology
(5)
Npj Breast Cancer
(4)
Blood
(3)
Chinese Medical Journal
(3)
Circulation
(3)
Nature Medicine
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Checkpoint blockade in the treatment of breast cancer: current status and future directions

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

Tissue-resident memory T cells in breast cancer control and immunotherapy responses

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy

Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions

Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

Clinical implications of prospective genomic profiling of metastatic breast cancer patients

Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer

Equitable Access to Genomic Molecular Testing for Australian Cancer Patients: Insights from the Victorian Precision Oncology Summit

Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies

Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer

Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients

Extended adjuvant aromatase inhibitor therapy: less is more

A pituitary metastasis, an adenoma and potential hypophysitis: A case report of tumour to tumour metastasis in the pituitary

Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm

Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012–2022

Advancing Immunotherapy in Metastatic Breast Cancer

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer

Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma

Suchergebnisse filtern